FASTING PLASMA C-PEPTIDE LEVEL PREDICTS THE RESPONSE OF GLUCAGON-LIKE PEPTIDE-1 AGONIST (EXENATIDE) ADD ON TO METFORMIN MONOTHERAPY IN OBESE TYPE 2 DIABETICS

Kağan GÜNGÖR; Serkan ÖZTÜRK; Bülent CAN; Mehmet SARGIN

FASTING PLASMA C-PEPTIDE LEVEL PREDICTS THE RESPONSE OF GLUCAGON-LIKE PEPTIDE-1 AGONIST (EXENATIDE) ADD ON TO METFORMIN MONOTHERAPY IN OBESE TYPE 2 DIABETICS

Authors : Kağan GÜNGÖR, Serkan ÖZTÜRK, Bülent CAN, Mehmet SARGIN

Pages : 798-802

View : 41 | Download : 8

Publication Date : 2022-08-30

Article Type : Research Paper

Abstract :Fasting Plasma C-peptide Level Predicts the Response of Glucagon-like Peptide-1 Agonist insert ignore into journalissuearticles values(Exenatide); Addition to Metformin Monotherapy in Obese Type 2 Diabetics ABSTRACT Aim: to evaluate the predictive ability of serum C-peptide level to attain glycemic control targets by adding a glucagon-like peptide-1 receptor agonist insert ignore into journalissuearticles values(GLP1-RA); to metformin monotherapy in patients with type 2 diabetes and obesity. Materials and methods: This is a retrospective study, in which we enrolled 44 consecutive obese type 2 diabetic patients who were on metformin monotherapy and have inadequate glycemic control insert ignore into journalissuearticles values(HbA1c >7% and <10%);. Twice daily GLP1-RA insert ignore into journalissuearticles values(10 mcg exenatide injection); was added to the treatment. Regardless of the initial HbA1c level, treatment success was considered as an HbA1c level below 7%. Results: When we compared the initial and the sixth month measurements of body weight, BMI, fasting glucose and c-peptide, we found a reduction for all parameters insert ignore into journalissuearticles values(p<0.01);. 27 insert ignore into journalissuearticles values(61.4%); patients were achieved treatment success. Baseline C-peptide level was correlated with HbA1c at sixth month insert ignore into journalissuearticles values(r:0.4, p:0.01);. Baseline fasting plasma c-peptide level was an independent predictor of successful glycemic control [exp.B: 6.6 insert ignore into journalissuearticles values(1.63-26-9); p:0.008]. Baseline plasma C-peptide level of 2.56 ng/mL was the best cut-off value for prediction of treatment success. Conclusion: Initial fasting plasma c-peptide level can predict the treatment response of the GLP1-RA add on to metformin monotherapy in obese type 2 diabetics. Keywords: C-peptide, type 2 diabetes, GLP-1 RA, exenatide
Keywords : C peptide, Diabetes, Obesity, GLP 1 receptor agonist, Exenatide

ORIGINAL ARTICLE URL